Byzen Digital Inc
Change company Symbol lookup
Select an option...
BYZN Byzen Digital Inc
XOM Exxon Mobil Corp
EPD Enterprise Products Partners LP
STLB Sterling Business Solutions Inc
CITY Avalon Correctional Services Inc
TEVJF Teva Pharmaceutical Industries Ltd
UMBF UMB Financial Corp
OXM Oxford Industries Inc
ICON Iconix Brand Group Inc
BAC Bank of America Corp
Go

Information Technology : IT Services |
Based in China
Company profile

Byzen Digital Inc. (formerly Emergency Pest Services Inc.) is a China-based company principally engaged in the development of a complete blockchain eco-system for Crypto requirements as its main objective. Byzen Digital Inc. has already made its first two acquisitions. Telecoin is a typical Crypto-currency company and Digi Ex is a company specialized in the marketing and promoting of Crypto-currencies. The Company help take its customers on a journey towards a much wider understanding of what Crypto and Blockchain technologies really are through its products. The Company also focuses to incorporate start-ups and small and medium-sized enterprises (SMEs) from the technology sectors, including cybersecurity, data storage, cloud-tech, analytics, software and digital applications.

Price
Delayed
$0.175
Day's Change
0.015 (9.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.189
Day's Low
0.151
Volume
(Heavy Day)

Today's volume of 606,039 shares is on pace to be much greater than BYZN's 10-day average volume of 898,364 shares.

606,039

New Player Cantourage Challenges Canopy Growth on Dronabinol Cannabis Monopoly in Europe

11:05 am ET April 27, 2020 (PR Newswire) Print

Since 15 April 2020, German pharmacies have been able to purchase the active ingredient dronabinol (also known as tetrahydrocannabinol or THC) directly from Cantourage - the new supplier of dronabinol, which is pure THC as an API (active pharmaceutical ingredient). Cantourage is therefore also helping to improve the supply situation in times of Corona. Dronabinol represents roughly 30% turnover of the overall medicinal cannabis market in Europe. Canopy Growth has acquired the dronabinol business of Bionorica in 2019 for 226 MEUR* and is now being challenged by the new competition with the best value proposition for pharmacies in Germany and Europe. Cantourage has its own exclusive production relationship with Israeli cannabis producer BOL (Breath of Life) Pharma for dronabinol, which pharmacies use to make patient-specific drugs. Cantourage was established by the former founders of Pedanios, Dr. Florian Holzapfel and Patrick Hoffmann, together with Norman Ruchholtz. In the past, they developed Pedanios into the European market leader for cannabis flowers and have sold Pedanios in 2017 to Aurora Cannabis. At Cantourage, they are now continuing the success story of medical cannabis in Europe and offer a new service for companies outside Europe.

https://mma.prnewswire.com/media/1160325/Cantourage_Think_Tank.jpg

The medical cannabis market in Germany is growing rapidly: It is expected that one million patients will be treated with medical cannabis in 2024**. Based on past developments, the sales volume for dronabinol will continue to multiply over the coming years. Demand for dronabinol in the European market has so far been met by just one manufacturer. Cantourage breaks this monopoly of Canopy Growth and strengthens the supply situation in times of Corona. The founding team of the new dronabinol supplier includes pioneers of the German medical cannabis market: Pedanios founders Dr. Florian Holzapfel and Patrick Hoffmann.

Dronabinol API Cantourage as drops or capsules for many indications

The active ingredient 'Dronabinol API Cantourage' is available for pharmacies to order directly from Cantourage and via wholesalers. Pharmacies process it mainly into either drops or capsules for patients according to the DAC monograph and dronabinol is therefore easier and more targeted to dose than cannabis flowers.

Dronabinol exclusively from Israel by BOL Pharma

Dronabinol API Cantourage is produced by BOL Pharma exclusively for Cantourage on a contract basis. BOL Pharma is by far the largest producer of medical cannabis in Israel and a strategic partner of Cantourage. The dronabinol produced for Cantourage is the first commercial export to the EU from Israel, which is considered a pioneer in medical cannabis, which has been approved for medical purposes since 1992. Up to now, medical cannabis in Germany came exclusively from Germany, Canada, the Netherlands and Portugal.

Tamir Gedo, CEO of BOL Pharma, is excited about entering the European market with Cantourage: "We are the market leader in Israel. The European market entry is the next logical step in our internationalization strategy. With Cantourage, we have found the ideal partner because we have known each other for several years and we are convinced by the team and its know-how."

First Pedanios, then Aurora, now Cantourage: the founding story and a think tank for cannabis companies outside of Europe

Dr. Florian Holzapfel and Patrick Hoffmann founded Pedanios in 2015, the first company in Germany to specialize in the distribution of medical cannabis. Within less than a year, Pedanios covered 80 percent of the entire market for medical cannabis flowers. In 2017, they sold Pedanios to the listed Canadian company Aurora Cannabis. Now, they are continuing to shape the medical cannabis market in Europe with Cantourage.

Dr. Florian Holzapfel sees the company as a think tank for cannabis: "Breaking the dronabinol monopoly is our first step towards creating added value for patients, pharmacists and health insurance companies." Norman Ruchholtz, CEO of Cantourage adds: "In addition, we offer a new service for companies outside of Europe to enter the European market with their products in a fast line process. We believe that this is especially important in times of Corona, when normal processes might be delayed." Together with suppliers, pharmacists and doctors, Cantourage sees itself as a community that pursues the well-being of patients - with the help of medical cannabis.

*(Source: https://www.bloomberg.com/press-releases/2019-05-02/dgap-news-bionorica-se-bionorica-sells-cannabis-business-to-canopy-growth) **(Source: Prohibition Partners 2019)

About Cantourage

Cantourage is a new player in the medical cannabis market in Germany. The company sees itself as a think tank that continues to shape the medical cannabis market in Germany and Europe with new ideas and concepts. Cantourage was founded in 2019 by Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann.

www.cantourage.com

Photo - https://mma.prnewswire.com/media/1160325/Cantourage_Think_Tank.jpg Logo - https://mma.prnewswire.com/media/1160322/Cantourage_Logo.jpg

Press contactPatrick HoffmannCo-founder and company spokesman E-Mail: press@cantourage.com Tel: +49 (0)30 / 49-85-50-68

https://mma.prnewswire.com/media/1160322/Cantourage_Logo.jpg

https://c212.net/c/img/favicon.png?sn=LN89932&sd=2020-04-27

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-player-cantourage-challenges-canopy-growth-on-dronabinol-cannabis-monopoly-in-europe-301047598.html

SOURCE Cantourage

https://rt.prnewswire.com/rt.gif?NewsItemId=LN89932&Transmission_Id=202004271105PR_NEWS_USPR_____LN89932&DateId=20200427

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.